Advertisement


Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

2024 ASCO Annual Meeting

Advertisement

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
ECHELON-3 was a Phase 3 double-blind placebo-controlled trial in patients with diffuse large B-cell lymphoma that had relapsed or refractory disease to prior therapy. In this study, they particularly enrolled those patients that were either ineligible for or had received prior treatment with both CAR-T cell therapy or hematopoietic stem cell transplant. In this trial, investigators evaluated a combination of lenalidomide and rituximab with either brentuximab vedotin or placebo. It was a median of three prior therapies, and in general the patients were heavily pre-treated, including approximately half of patients having primary refractory disease, 30% of patients with prior CAR-T cell exposure, and approximately 15% of patients had prior bispecific antibody exposure. We see with the combination of brentuximab vedotin, lenalidomide and rituximab, that this is a very active regimen, and we're seeing high complete response rates along with encouraging durability at this point. These improved responses were encouragingly seen in both CD30-positive and CD30-negative patients, and this translated into an improvement in progression-free along with overall survival. And importantly, we saw some improvements in really key subsets of patients with high-risk features such as those with high IPI, those patients with prior CAR-T exposure, along with those patients with nongerminal center cell of origin, and this regimen though was not without its own toxicity, and we saw higher incidence of Grade 3 or greater adverse events in the [inaudible 00:01:40] and rituximab arm compared to lenalidomide-rituximab alone, particularly those manifested as hematologic toxicity, along with increased risk of peripheral neuropathy. In general this was an active regimen, and is particularly encouraging for those patients that may not be either eligible for, or have previously received, therapy with things like bispecific antibodies, CAR-T or hematopoietic stem cell transplant. This is currently an interim analysis, and we will need longer follow-up in order to have a better understanding of long-term outcomes, particularly in terms of both safety and efficacy.

Related Videos

Breast Cancer

Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial

Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).

Skin Cancer

Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study

Omid Hamid, MD, of The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, discusses updated data on IMC-F106C, a novel bispecific protein that, in a phase I safety and efficacy study, exhibited clinical activity in patients with unresectable or metastatic cutaneous melanoma who were pretreated with immune checkpoint inhibitors. A phase III trial of IMC-F106C with nivolumab in the first-line setting of metastatic disease has been initiated (NCT06112314; Abstract 9507).

Colorectal Cancer

Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone

Andrea Cercek, MD, of Memorial Sloan Kettering Cancer Center, discusses expanded data on the durability of complete response to dostarlimab-gxly, a PD-1 single-agent therapy administered to patients with locally advanced mismatch repair–deficient rectal cancer. The drug yielded recurrence-free responses, lasting longer than a year, without the need for chemotherapy, radiation, or surgery (LBA3512).

Breast Cancer

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Dejan Juric, MD, of the Massachusetts General Hospital Cancer Center, discuss phase III findings on first-line use of inavolisib or placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer who relapsed within 12 months of completing adjuvant endocrine therapy (Abstract 1003).

Lymphoma

David J. Andorsky, MD, on DLBCL and FL: New Data on Use of Subcutaneous Epcoritamab

David J. Andorsky, MD, of the Sarah Cannon Research Institute and Rocky Mountain Cancer Centers, discusses EPCORE NHL-6, an ongoing study of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). As outpatients, the study participants were given subcutaneous epcoritamab-bysp to see whether they could be safely monitored and cytokine-release syndrome appropriately managed in the outpatient setting (Abstract 7029).

Advertisement

Advertisement




Advertisement